Progress and challenges towards targeted delivery of cancer therapeutics

Area of Science:

• Oncology
• Nanotechnology
• Drug Delivery

Background:

• Targeted delivery systems for cancer therapeutics have advanced significantly in preclinical research.
• Despite numerous successful preclinical studies, clinical translation remains a significant hurdle.
• Only a limited number of passively targeted nanocarriers (NCs) have gained clinical approval, with no actively targeted NCs progressing beyond clinical trials.

Purpose of the Study:

• To review the fundamental principles of targeted delivery strategies for cancer therapeutics.
• To identify potential reasons behind the limited clinical success of targeted nanocarriers.
• To propose essential criteria for the development of novel actively targeted nanocarriers.

Main Methods:

• Literature review of targeted delivery approaches in cancer therapy.
• Analysis of factors limiting clinical translation of nanocarriers.
• Formulation of criteria for designing effective actively targeted nanocarriers.

Main Results:

• Preclinical success of targeted nanocarriers does not consistently translate to clinical efficacy.
• Key challenges include biological barriers, off-target effects, and manufacturing complexities.
• Lack of standardized criteria for active targeting hinders development.

Conclusions:

• Actively targeted nanocarriers require rigorous evaluation beyond preclinical models.
• Development must consider specific tumor microenvironments and patient heterogeneity.
• Future strategies should focus on robust design principles and clinical validation for successful tumor targeting.